Amneal Pharmaceuticals, Inc.
HealthcareNASDAQ:AMRX · NASDAQ Global Select
-$0.14 today
Vol 2.24M · Avg 1.74M
Balance Sheet
Inspect the capital base behind the business
Review assets, liabilities, equity, cash, and debt to judge whether the company has the financial position to support future returns.
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $197.7M |
| Receivables | $902.7M |
| Inventory | $641.6M |
| Other Current | $56.0M |
| Total Current Assets | $1.8B |
| PP&E (Net) | $558.8M |
| Goodwill | $593.8M |
| Intangible Assets | $534.9M |
| Other Non-current | $54.9M |
| Total Non-current Assets | $1.7B |
| Total Assets | $3.5B |
Analysis
Selected assets total $3.5B for Latest. The largest visible component is Receivables at $902.7M, about 25.5% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Balance Sheet
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $310.9M +181.2% | $110.6M +20.8% | $91.5M +252.4% | $26.0M -89.5% | $247.8M | $1.0B | $841.8M | $673.8M |
| Short-term Investments | $0 -100.0% | $1.9M -15.1% | $2.2M +20.8% | $1.8M | $0 | -$1.6B | $445.6M | $378.4M |
| Net Receivables | $939.9M +21.2% | $775.7M +20.1% | $645.7M -13.0% | $741.8M +6.8% | $694.7M | $533.8M | $399.4M | -$1.7B |
| Inventory | $606.3M -1.0% | $612.5M +5.3% | $581.4M +9.5% | $530.7M +8.4% | $489.4M | $641.6M | $328.0M | $316.8M |
| Other Current Assets | $4.4M -89.1% | $40.7M +438.0% | $7.6M -88.2% | $64.4M +53.4% | $41.9M | $1.5B | $966.4M | $764.8M |
| Total Current Assets | $1.9B +20.4% | $1.6B +15.2% | $1.4B -2.4% | $1.4B -7.1% | $1.5B | $12.5B | $10.5B | $5.5B |
| Property, Plant & Equipment (Net) | $550.3M +5.1% | $523.7M -4.8% | $550.1M -6.7% | $589.4M -7.8% | $639.0M | $1.2B | $1.5B | $687.8M |
| Goodwill | $595.5M -0.3% | $597.4M -0.2% | $598.6M -0.0% | $598.9M +1.0% | $593.0M | $925.8M | $466.6M | $309.8M |
| Intangible Assets | $563.5M -23.1% | $732.4M -17.7% | $890.4M -18.8% | $1.1B -6.1% | $1.2B | $568.8M | $860.0M | $1.5B |
| Long-term Investments | $7.8M -78.2% | $35.9M -3.1% | $37.1M -56.7% | $85.6M | $0 | $524.0M | -$1.5B | $860.0M |
| Tax Assets | $0 | $0 | $0 | $0 | $0 | $1.5B | $1.4B | $1.4B |
| Other Non-current Assets | $50.0M +106.4% | $24.2M +31.4% | $18.4M +4.5% | $17.6M -14.5% | $20.6M | $1.4B | $1.0B | $679.4M |
| Total Non-current Assets | $1.8B -7.7% | $1.9B -8.6% | $2.1B -12.3% | $2.4B -1.3% | $2.4B | -$15.3B | $14.8B | $11.3B |
| Total Assets | $3.7B +5.1% | $3.5B +0.8% | $3.5B -8.6% | $3.8B -3.6% | $3.9B | $13.3B | $11.9B | $10.6B |
| Account Payables | $254.7M -2.0% | $259.8M +81.0% | $143.6M -13.9% | $166.8M +27.3% | $131.1M | $1.3B | -$1.5B | $1.4B |
| Short-term Debt | $21.6M -93.3% | $324.2M +52.1% | $213.1M +136.9% | $90.0M +193.9% | $30.6M | -$1.6B | -$1.6B | $326.6M |
| Tax Payables | $0 | $0 | $0 | $0 -100.0% | $2.5M | $574.4M | -$1.5B | $1.4B |
| Deferred Revenue | $0 | $0 -100.0% | $398.4M | $0 | $0 | -$1.6B | $374.2M | $542.2M |
| Other Current Liabilities | $525.5M +136.3% | $222.4M +5590.0% | $3.9M -98.5% | $263.1M +119.1% | $120.1M | $1.1B | $1.5B | $493.2M |
| Total Current Liabilities | $881.6M -22.0% | $1.1B +33.4% | $846.6M +12.5% | $752.8M +11.2% | $677.2M | $6.0B | $10.1B | $14.3B |
| Long-term Debt | $2.6B +20.9% | $2.2B -10.9% | $2.4B -7.8% | $2.6B -3.2% | $2.7B | $1.3B | $438.6M | $1.3B |
| Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $746.6M | $612.2M | $477.8M |
| Deferred Revenue (Non-current) | $0 | $0 | $0 | $0 | $0 | -$1.6B | $715.8M | $1.3B |
| Other Non-current Liabilities | $75.8M -53.6% | $163.3M +291.0% | $41.8M -57.0% | $97.1M +48.4% | $65.4M | $489.0M | $1.1B | -$1.5B |
| Total Non-current Liabilities | $2.8B +15.5% | $2.4B -5.8% | $2.6B -9.6% | $2.8B -2.0% | $2.9B | $3.9B | $7.5B | $14.1B |
| Total Liabilities | $3.7B +3.6% | $3.5B +3.9% | $3.4B -5.0% | $3.6B +0.5% | $3.6B | $14.7B | $3.7B | $9.6B |
| Common Stock | $3.1M +1.5% | $3.1M +1.1% | $3.1M +1.0% | $3.0M +0.7% | $3.0M | $651.4M | $517.0M | $382.6M |
| Retained Earnings | -$535.0M +11.9% | -$607.1M -23.8% | -$490.2M -20.7% | -$406.2M -47.1% | -$276.2M | -$1.6B | $519.8M | $1.1B |
| Accumulated OCI | -$110.7M -69.0% | -$65.5M -102.5% | -$32.3M -425.5% | $9.9M +140.0% | -$24.8M | $393.8M | $550.6M | $707.4M |
| Other Stockholders Equity | $0 | $0 | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Minority Interest | $76.8M +18.6% | $64.7M +55.9% | $41.5M +146.4% | -$89.5M -1449.2% | $6.6M | $1.4B | $337.8M | $931.4M |
| Total Equity | $6.0M +113.4% | -$44.5M -172.7% | $61.3M -70.7% | $208.9M -43.1% | $367.0M | $9.1B | $7.7B | $3.3B |
| Total Debt | $2.7B +5.5% | $2.6B -5.7% | $2.8B -3.3% | $2.8B -1.1% | $2.9B | $724.2M | $410.6M | $399.4M |
| Net Debt | $2.4B -2.3% | $2.5B -6.6% | $2.7B -5.7% | $2.8B +7.3% | $2.6B | $389.6M | $501.6M | $311.2M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Lantheus Holdings, Inc.
NASDAQ:LNTH
$6.80B
Mirum Pharmaceuticals, Inc.
NASDAQ:MIRM
$4.99B
Indivior Pharmaceuticals Inc
NASDAQ:INDV
$4.80B
Envista Holdings Corp
NYSE:NVST
$4.00B
Telix Pharmaceuticals Limited
NASDAQ:TLX
$3.24B
Dyne Therapeutics, Inc.
NASDAQ:DYN
$3.01B
Soleno Therapeutics, Inc.
SLNO
$2.76B
Supernus Pharmaceuticals, Inc.
NASDAQ:SUPN
$2.58B
Bausch Health Companies Inc.
NYSE:BHC
$1.89B
Perrigo Company plc
NYSE:PRGO
$1.52B
SEC Filings
Recent regulatory filings
No filings found.
How much cash does AMRX have?
Amneal Pharmaceuticals, Inc. (AMRX) reported $310.87M in cash and equivalents in fiscal 2025.
How much debt does AMRX carry?
Amneal Pharmaceuticals, Inc. (AMRX) reported $2.74B of total debt, with net debt of $2.43B.
Explore More
Continue the stock analysis
Jump to another research area for this company.